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Abstract
Pharmacological cognitive enhancement (PCE) refers to the nonmedical use of prescription
or recreational drugs to enhance cognitive performance. Several concerns about PCE have
been raised in the public. The aim of the present study was to investigate students’ attitudes
toward PCE. Students at three Swiss universities were invited by e-mail to participate in a
web-based survey. Of the 29,282 students who were contacted, 3,056 participated. Of
these students, 22% indicated that they had used prescription drugs (12%) or recreational
substances including alcohol (14%) at least once for PCE. The use of prescription drugs or
recreational substances including alcohol prior to the last exam was reported by 16%.
Users of pharmacological cognitive enhancers were more likely to consider PCE fair (24%)
compared with nonusers (11%). Only a minority of the participants agreed with the nonmed-
ical use of prescription drugs by fellow students when assuming weak (7%) or hypothetically
strong efficacy and availability to everyone (14%). Two-thirds (68%) considered perfor-
mance that is obtained with PCE less worthy of recognition. Additionally, 80% disagreed
that PCE is acceptable in a competitive environment. More than half (64%) agreed that
PCE in academia is similar to doping in sports. Nearly half (48%) claimed that unregulated
access to pharmacological cognitive enhancers increases the pressure to engage in PCE
and educational inequality (55%). In conclusion, Swiss students’ main concerns regarding
PCE were related to coercion and fairness. As expected, these concerns were more preva-
lent among nonusers than among users of pharmacological cognitive enhancers. More bal-
anced information on PCE should be shared with students, and future monitoring of PCE is
recommended.
Introduction
The nonmedical use of prescription drugs or recreational drugs to improve cognitive perfor-
mance is referred to as pharmacological cognitive enhancement (PCE), which is often
PLOSONE | DOI:10.1371/journal.pone.0144402 December 10, 2015 1 / 13
OPEN ACCESS
Citation: Maier LJ, Liakoni E, Schildmann J, Schaub
MP, Liechti ME (2015) Swiss University Students’
Attitudes toward Pharmacological Cognitive
Enhancement. PLoS ONE 10(12): e0144402.
doi:10.1371/journal.pone.0144402
Editor: Kent E. Vrana, Penn State College of
Medicine, UNITED STATES
Received: August 18, 2015
Accepted: November 17, 2015
Published: December 10, 2015
Copyright: © 2015 Maier et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This study was supported by internal funds
from the Division of Clinical Pharmacology &
Toxicology, University Hospital Basel (ML), Swiss
Centre of Applied Human Toxicology (SCAHT) (ML),
and Swiss Research Institute for Public Health and
Addiction (ISGF), Zurich (MS). The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
discussed in terms of ethical considerations and morality [1–4]. The public has raised strong
concerns about the fairness and coercion of drug use for PCE [5].
Schelle et al. (2014) summarized evidence from 40 studies that contained information about
public attitudes toward PCE. Aside from concerns regarding fairness and coercion, concerns
were most often raised about the medical safety of substances that are used for PCE [5].
The prevalence of PCE among Swiss university students and their perceived pressure to use
drugs for PCE were recently investigated by two web-based studies [6,7]. Both studies also
included a small set of questions to examine students’ concerns about PCE in general, not dif-
ferentiating between substances and different situations of use. Students worried about the
medical safety of drugs that are used for PCE and reported perceiving peer pressure to use
drugs for PCE [6,7]. Users of pharmacological cognitive enhancers were less concerned about
side effects and potential disadvantages in those who refuse to use PCE compared with nonus-
ers [7]. However, PCE among students might be considered cheating, resulting in inequality
and injustice, potentially inauthentic results, or peer pressure to engage in PCE [5,7,8]. Infor-
mation on attitudes toward PCE use was obtained with mostly small study samples, and only
few empirical studies have assessed a wider range of students’ attitudes toward PCE in terms of
the acceptability of the many different substances that are used for PCE [5,9]. Furthermore,
only a few studies have compared PCE in academia with doping in sports [10–12]. Similar to a
study among 1,026 German students, qualitative interviews among 19 Australian university
students revealed that PCE was considered unfair, and monitoring and regulating PCE were
rated as important [13,14]. In contrast, interviews with 18 healthy German students who used
prescription drugs for PCE revealed that students see a moral difference between PCE with
drugs and PCE with caffeine [9].
Most of the studies that have been performed to date were rather small and addressed only a
few concerns regarding PCE in general and not specifically for different substances, as reported
in a recent review [5]. Therefore, we addressed students’ attitudes toward various types of phar-
macological cognitive enhancers among Swiss university students in a large, empirical, web-
based survey, including quantitative ratings for each statement to allow statistical comparisons.
We examined a series of specific statements regarding the acceptability of different drugs that
are used for PCE and the implications of various situations of use. We also investigated atti-
tudes concerning the authenticity of performance that is achieved with PCE, fairness, auton-
omy, and the need for regulation. We adjusted and included several questions that were used
in previous interviews [10,13] and a quantitative study among German students [14] to com-
pare our findings with previous international studies. We also investigated the frequency of the
nonmedical use of prescription and recreational drugs [6] to statistically compare attitudes
toward PCE between users and nonusers of pharmacological cognitive enhancers. Our primary
hypothesis was that users of pharmacological cognitive enhancers would exhibit more accept-
ing attitudes toward PCE compared with nonusers [5,7].
Materials and Methods
Recruitment of study participants
Students at the University of Zurich (UZH; total of 5,000 contacted), University of Basel (Uni-
Bas; total of 11,189 contacted), and Swiss Federal Institute of Technology Zurich (ETHZ; total
of 13,093 contacted) were contacted via e-mail and invited to participate in an online survey on
attitudes toward PCE. In the e-mail, potential participants were briefly informed that we were
interested in students’ attitudes toward PCE, regardless of whether they were experienced with
PCE or not. The participants were informed that participation in the study was voluntary, that
responses would be anonymous and stored on a secure server, and that the study was
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authorized by the Ethics Committee of the Philosophical Faculty of the University of Zurich
and Ethics Committee of the Cantons of Basel. All of the study participants provided informed
consent when they left the study information webpage to start the survey. No incentives were
provided for participation in the study. The participants were informed that completion of the
questionnaire would take approximately 15 min.
Measures (questionnaire)
The full study questionnaire is provided online (S1 Questionnaire). Question identifiers are
included below in parentheses.
Definition of pharmacological cognitive enhancement. At the beginning of the ques-
tionnaire, PCE was defined as the use of prescription drugs (e.g., methylphenidate) or other
psychoactive substances (e.g., alcohol, cannabis, and cocaine) to enhance cognitive perfor-
mance (e.g., attention, concentration, vigilance, and reduction of nervousness) while studying,
similar to our previous study [6]. Coffee and energy drinks were not considered for this narrow
definition of PCE, but their rates of use and attitudes concerning their use were assessed for
comparison.
Participant characteristics. The participants were first asked to indicate their (Q1) uni-
versity, (Q2-4) study major, (Q5) number of semesters studied, (Q6) age, (Q7) sex, (Q8)
whether they studied full-time or part-time, and (Q9) whether they worked (percentage of full-
time employment).
Prevalence of pharmacological cognitive enhancement. Participants’ drug use that was
aimed at improving study performance was assessed similarly to our previous study on PCE
among Swiss university students [6]. Specifically, the participants were asked to indicate
whether they had ever used one or more of the following (Q13) prescription drugs without a
medical indication to improve cognitive performance while studying: methylphenidate, moda-
finil, antidepressants, anti-dementia drugs, sedatives/sleeping pills, and beta-blockers. They
were also asked whether they had ever used any of the following (Q14) recreational drugs to
improve cognitive performance while studying: alcohol, cannabis products, cocaine, illegal
amphetamine, and methylenedioxymethamphetamine (MDMA). If the participants indicated
that any substance was used explicitly for PCE, then they were subsequently asked (i) how
often PCE occurred within the last 30 days prior to the last exam, (ii) whether their expecta-
tions regarding the efficacy of the substance that they used were met, and (iii) whether they
would consider repeated use in a similar situation.
Attitudes toward pharmacological cognitive enhancement. The participants were asked
to rate a series of statements that reflected different attitudes toward various types of PCE in
various contexts of use. Several statements were adjusted from previous studies [13–15] and
pilot-tested for comprehension and redundancy. The participants rated each statement on a
Likert scale, indicating their agreement (1 = strongly disagree, 5 = strongly agree).
Substances used to improve cognitive performance while studying. First (Q15), the par-
ticipants were asked to indicate their agreement with the use of one of the following substances:
the prescription drug methylphenidate or modafinil with or without a prescription, illegal stim-
ulants (e.g., amphetamine, cocaine, MDMA), coffee, caffeine tablets, and energy drinks. The
participants were informed that they should assume that these substances generally have only
weak effects on cognitive performance, in line with scientific data [16–18].
Case vignette: “Thomas”. Second (Q16), a “real-world” and prototypic vignette of PCE
was presented that described a student, “Thomas,” who was studying for his final exam using
non-prescribed methylphenidate. The example was taken from a previous qualitative interview
study [15] and adjusted for the present study to allow for quantitative assessments. Thomas
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had concentration problems and complained to a colleague about feeling pressured and having
problems learning the material for the exam. His friend recommended that Thomas should use
methylphenidate to assist with studying and offered him some. Thomas used the methylpheni-
date and felt that it facilitated concentration over longer periods of time. He felt that he was
more efficient at learning and less afraid of the exam. Thomas passed the exam with even better
grades than previously. The participants were asked (i) whether they agreed with Thomas’ use
of methylphenidate in this situation in general, (ii) whether it would have been acceptable to
use methylphenidate with a doctor’s prescription but without a diagnosed disorder, and (iii)
whether it would have been acceptable to use methylphenidate with a prescription and diag-
nosed attention deficit disorder.
Contexts of pharmacological cognitive enhancement, assuming hypothetically strong
efficacy and legal availability. The participants then had to indicate their attitudes toward
PCE with regard to different contexts of use, assuming that substances with strong cognitive-
enhancing effects existed (which is currently not the case) that are legally available to everyone
(Q17). Thus, the participants were asked whether they agreed with the use of an effective sub-
stance for cognitive enhancement (i) by any fellow students, (ii) by fellow students with bad
grades, (iii) by fellow students who were diagnosed with a mental disorder (i.e., attention defi-
cit), (iv) by fellow students with a mental disorder without a physician’s diagnosis, (v) by a sur-
geon to improve performance during long operations or night shifts, or (vi) by professors to
enhance academic teaching/learning performance.
General attitudes toward pharmacological cognitive enhancement. The participants
then rated a series of statements on general attitudes toward PCE. They were asked whether
they agreed or disagreed (Q18) that PCE negatively alters the quality of an academic result
(e.g., less authentic), (Q19) that substances that are used for PCE change emotions and social
behavior of users, (Q20) that substances that are used for PCE change the personality of users,
(Q21) that achievements with PCE are less worthy of recognition than similar achievements
without substance use, (Q22) that someone who uses substances to study longer has planned
his work poorly, (Q23) that substances that are used to improve studying hinder the acquisition
of more sustainable planning and learning strategies, and (Q24) that mankind has always used
substances to enhance performance (e.g., coffee, coca, betel, tobacco) and the use of modern
substances, such as medications, is simply the most recent form of this phenomenon.
The participants then indicated (Q25) whether they considered PCE (25a) generally
unproblematic and acceptable, (25b) unproblematic as long as the substances were safe, (25c)
unproblematic as long as use is controlled and occasional, or (25d) unproblematic as long as
no adverse effects caused harm to others (e.g., impaired driving skills).
Comparison with doping in sports. The participants were then asked (Q26) to compare
PCE in academia with doping in sports using two partially contrasting statements. First, they
had to indicate whether they considered PCE in academia as similar to doping in sports. Sec-
ond, they were asked whether they agreed or disagreed with the statement that winners and los-
ers exist in sports only, whereas in academia PCE that leads to success does not necessarily
mean that others lose. Similarly, participants had to indicate (Q27) whether they consider PCE
acceptable in a non-competitive environment where one’s own performance is not measured
relative to someone else’s performance and in a competitive environment where one’s own per-
formance is assessed relative to someone else’s performance.
Autonomy vs. regulation. Additionally (Q28), the participants shared their opinions
about PCE and autonomy: (28a) individuals are autonomous, and everybody should be free to
decide whether to use substances for cognitive enhancement or not, and (28b) they would not
mind if other students took substances while studying. A set of statements then explored opin-
ions about regulating PCE: (28c) the university should regulate substance use for the purpose
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of improving cognitive performance among students, (28d) unregulated access to substances
that are used for cognitive enhancement might result in unequal chances with regard to educa-
tion and professional life, (28e) unregulated access to substances that are used for cognitive
enhancement increases pressure to use these substances (coercion), and (28f) access to medica-
tions and other substances is already sufficiently regulated; hence, specific regulations for PCE
are unnecessary.
Duties of academic institutions. The participants were then asked (Q29) whether perfor-
mance requirements at universities might increase because of PCE, (Q30) whether more
investment in research that seeks to develop effective substances that increase cognitive perfor-
mance is desirable, and (Q31) whether universities should collect data on the importance
(prevalence/acceptance) of PCE among students to neutrally inform students about this topic
and potential harms. Finally, the participants were asked (Q32) whether they would consider
using substances for PCE that are safe and have few adverse effects, even if they would gain an
advantage over others. The participants also had to indicate whether (Q33) they considered
that PCE reflects media hype with no real relevance to society.
Statistical analysis
Analyses were conducted using Statistica 12 software (StatSoft, Tulsa, OK, USA). Likert scales
were used to measure attitudes toward PCE and are expressed as numeric scores: 1 = “strongly
disagree,” 2 = “rather disagree,” 3 = “unsure,” 4 = “rather agree,” and 5 = “strongly agree.” To
determine agreement (> 3) or disagreement (< 3) with a statement, the mean rating for each
statement was tested against 3 using t-tests for single means. Differences in attitudes toward
different types or contexts of PCE were assessed using nonparametric Friedman analyses of
variance (ANOVAs) or Wilcoxon matched-pairs tests. Differences in attitudes between PCE
users and nonusers were assessed using Kruskal-Wallis tests. The number (%) of participants
who agreed or disagreed with a statement was determined for all statements with scores of 1 or
2 (indicating disagreement) and scores of 4 or 5 (indicating agreement). Multiple regression
analysis was used to examine participant characteristics that predict agreement with the use of
pharmacological cognitive enhancers in the case example (Q16). To account for multiple test-
ing, the level of significance was set to p< 0.001 for all of the analyses.
Results
Participant characteristics
Response rates and participant characteristics are presented in S1 Table. A total of 3,056 stu-
dents who completed at least the section on the use of pharmacological cognitive enhancers in
the questionnaire were included in the study. The participants were 17–72 years old (mean, 23
years). The median number of completed semesters was six (range, 1–24). An equal number of
male and female students participated in the study. Most of the participants from UniBas and
UZH were female, and most of the participants from ETHZ were male. Most of the students
were enrolled full-time, with a higher percentage of part-time students and employed students
at the universities compared with ETHZ (S1 Table).
Twenty-two percent of the participants reported having used prescription or recreational
drugs at least once for the purpose of improving cognitive performance while studying. Addi-
tionally, 12% reported the nonmedical use of prescription drugs, and 14% reported using alco-
hol and illegal drugs for PCE. Alcohol, methylphenidate, cannabis, and sedatives were the
substances that were most commonly used for PCE (S2 Table). A total of 498 students (16.3%)
reported the use of pharmacological cognitive enhancers prior to the last exam, including
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prescription drugs in 218 cases (7.1%) and recreational drugs (including mainly alcohol) in 334
cases (10.9%).
Attitudes toward pharmacological cognitive enhancement
Likert scale ratings on attitudes toward PCE are listed in Table 1 for all participants and sepa-
rately for users and nonusers of pharmacological cognitive enhancers, together with the test
statistics. Additionally, numbers (percentages) of subjects who agreed or disagreed with a state-
ment are shown in S3 Table.
Attitudes toward substance use for cognitive enhancement depended on the type of sub-
stance used (Table 1). Freely available substances, such as coffee and energy drinks, were most
acceptable when used while studying. Caffeine tablets were also rated as rather acceptable
(Table 1). The use of methylphenidate or modafinil for PCE was not advocated, especially
when used without a prescription. Illegal stimulants were the least acceptable type of drug for
PCE. Attitudes toward PCE were strongly related to personal experiences with PCE. Assuming
weak efficacy, drug use for PCE was rated as more acceptable by experienced users compared
with nonusers (Table 1).
In the case vignette of “Thomas,” nonmedical methylphenidate use for PCE was considered
unacceptable, except by students who used PCE prior to the last exam (Table 1). Moreover,
38% of students who engaged in PCE prior to the last exam and 25% of students who engaged
in PCE overall agreed with using non-prescribed methylphenidate for PCE, whereas only 9%
of nonusers agreed (S3 Table). Students were slightly more tolerant of methylphenidate use for
PCE if it was prescribed by a physician, even without having a diagnosed mental disorder
(Z = 13.5, p< 0.001). When prescribed based on a diagnosed attention deficit disorder, methyl-
phenidate use was the most acceptable and clearly more acceptable than non-prescribed use
(Z = 40.9, p< 0.001) or prescribed use without a diagnosis (Z = 40.5, p< 0.001; Table 1). Stu-
dents who engaged in PCE considered the use of methylphenidate for PCE in the example of
“Thomas” as more acceptable than nonusers, independent of whether it had been prescribed or
not (Table 1). Multiple regression analysis revealed that agreement with PCE was more likely
among students who were experienced with PCE (F = 246.4, p< 0.001) and among male stu-
dents (F = 448.0, p< 0.001), whereas age, the number of semesters studied, and being
employed had no influence on whether students agreed with PCE.
For the hypothetical case of legally available substances with strong effects on cognitive per-
formance, PCE was considered acceptable only by fellow students with a diagnosis of a mental
disorder (Table 1). Pharmacological cognitive enhancement by fellow students with mental dis-
orders that were diagnosed by a physician (Z = 40.8, p< 0.001) or without a formal diagnosis
(Z = 25.1, p< 0.001) were considered more acceptable compared with PCE by any fellow stu-
dent, and a formal diagnosis enhanced the acceptability of PCE (Table 1). Interestingly, PCE
was considered slightly less unacceptable by fellow students with bad grades (Z = 7.8,
p< 0.001) compared with PCE by fellow students in general. Students rather disagreed with
substance use for enhanced performance by surgeons, but disagreement with PCE by academic
professors was even more pronounced (Z = 23.7, p< 0.001). In all six contexts of use that were
presented in the survey, students who were experienced with PCE were more likely to agree
with substance use for performance enhancement compared with nonusers (Table 1).
Respondents did not support the view that PCE negatively alters the quality of an academic
result (Table 1). Nevertheless, students who had never used drugs for PCE considered results
that are achieved with PCE as less worthy of recognition (Table 1). Additionally, students were
concerned that PCE might change the feelings and behavior of users and potentially affect their
personality. Students who never used drugs for PCE were more likely to agree with the
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Table 1. Students‘ attitudes toward pharmacological cognitive enhancement (PCE).
Total
(2,999)
PCE prior to the
last exam (223)
PCE but not prior to
the last exam (425)
Never used
PCE (2,351)
Kruskal-Wallis
test: H =
Acceptability of substances used while
studying (assuming rather weak efﬁcacy)
N = 2,933 n = 223 n = 425 n = 2,285
Coffee 4.2 (1.1) 4.3 (1.1) 4.3 (1.1) 4.1 (1.1) 17, P<0.001
Energy drinks 3.7 (1.3) 3.9 (1.3) 3.9 (1.3) 3.7 (1.3) 18, P<0.001
Caffeine tablets 3.1 (1.3) 3.6 (1.4)* 3.3 (1.3)* 3.0 (1.3) 56, P<0.001
Methylphenidate or modaﬁnil as a prescribed
medication
2.4 (1.4) 3.0 (1.5) 2.7 (1.5) 2.2 (1.4) 89, P<0.001
Methylphenidate or modaﬁnil without a prescription 1.6 (0.9) 2.3 (1.4)* 1.9 (1.2)* 1.4 (0.9) 89, P<0.001
Illegal stimulants (amphetamine, cocaine, or
MDMA)
1.3 (0.7) 1.9 (1.2)* 1.5 (1.0)* 1.3 (0.7) 162, P<0.001
Case example of a student using
methylphenidate while studying
N = 2,880 n = 222 n = 419 n = 2,239
It is acceptable to use methylphenidate without a
prescription
2.0 (1.2) 2.9 (1.6)* 2.5 (1.4)* 1.9 (1.1) 156, P<0.001
It is acceptable with a prescription even if no
mental disorder has been diagnosed
2.3 (1.3) 2.8 (1.5)* 2.6 (1.4)* 2.2 (1.2) 73, P<0.001
It is acceptable with a prescription and with a
diagnosed mental disorder
4.0 (1.2) 4.1 (1.2) 4.1 (1.2) 4.0 (1.2) 12, P<0.001
Contexts of PCE use (assuming hypothetically
strong effects & availability)
N = 2,772 n = 209 n = 392 n = 2,171
PCE is fair if fellow students use effective
substances
2.0 (1.2) 2.8 (1.5)* 2.4 (1.4)* 1.9 (1.1) 115, P<0.001
PCE is fair if fellow students have poor grades 2.1 (1.3) 2.9 (1.5)* 2.5 (1.4)* 2.0 (1.2) 112, P<0.001
PCE is fair if fellow students have a diagnosed
mental disorder
3.8 (1.1) 4.1 (1.1)* 3.9 (1.1)* 3.7 (1.1) 37, P<0.001
PCE is fair if fellow students have a mental
disorder but no diagnosis
2.6 (1.3) 3.2 (1.4)* 2.9 (1.4)* 2.5 (1.3) 82, P<0.001
PCE is fair if surgeons have long operations or
night shifts
2.7 (1.4) 3.1 (1.6)* 2.9 (1.5)* 2.6 (1.4) 32, P<0.001
PCE is fair if professors improve their academic
teaching skills/ learning
2.1 (1.3) 2.8 (1.5)* 2.5 (1.4)* 2.0 (1.2) 96, P<0.001
General attitudes toward PCE N = 2,601 n = 195 n = 366 n = 2,040
PCE negatively alters the quality of the academic
result
2.8 (1.1) 2.7 (1.2) 2.8 (1.1) 2.9 (1.1) NS
PCE changes feelings and social behaviour 3.7 (1.0) 3.7 (1.1) 3.8 (1.0) 3.7 (0.9) NS
PCE changes the personality 3.3 (1.1) 3.1 (1.2) 3.3 (1.1) 3.4 (1.0) NS
Results obtained with PCE are less worthy of
recognition
3.9 (1.3) 3.1 (1.6)* 3.5 (1.4)* 4.0 (1.2) 83, P<0.001
Someone who needs PCE poorly planned his work 3.2 (1.3) 2.6 (1.4)* 2.9 (1.3)* 3.3 (1.3) 77, P<0.001
PCE hinders acquisition of planning and learning
skills
3.6 (1.2) 3.1 (1.4)* 3.4 (1.3)* 3.7 (1.1) 56, P<0.001
Mankind always used substances to enhance
performance, PCE is not new
2.5 (1.3) 3.1 (1.4)* 2.8 (1.4)* 2.4 (1.2) 68, P<0.001
PCE is generally unproblematic and acceptable 1.8 (1.0) 2.4 (1.3)* 2.1 (1.1)* 1.7 (0.9) 103, P<0.001
PCE is unproblematic as long as the substances
are safe
2.3 (1.3) 2.8 (1.4)* 2.7 (1.3)* 2.2 (1.2) 72, P<0.001
PCE is unproblematic as long as the use occurs
controlled and occasionally
2.6 (1.3) 3.1 (1.4)* 3.0 (1.4)* 2.4 (1.2) 95, P<0.001
PCE is unproblematic as long as it causes no harm
to others
2.4 (1.3) 3.0 (1.5)* 2.8 (1.4)* 2.3 (1.2) 87, P<0.001
Comparison with doping in sports N = 2,561 n = 191 n = 357 n = 2,013
(Continued)
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statement that users of pharmacological cognitive enhancers did not plan their work suffi-
ciently and that acquiring planning and learning skills was hindered by PCE. However, more
than half of students who used drugs for PCE prior to their last exam disagreed that PCE is
associated with poorly planned work. Neither users nor nonusers of pharmacological cognitive
enhancers considered PCE unproblematic and acceptable overall. Both users and nonusers dis-
agreed with the statement that PCE was unproblematic, as long as the substances that are used
are safe. Even controlled and occasional PCE was not rated unproblematic. Finally, the view
that an individual’s use of pharmacological cognitive enhancers was unproblematic as long as
no negative consequences for others occurred was not supported by nonusers, whereas stu-
dents with experience of PCE had no clear opinion (Table 1).
Sixty-four percent of the participants considered PCE in academia as similar to doping in
sports (S3 Table). Importantly, PCE was considered unacceptable in a competitive
Table 1. (Continued)
Total
(2,999)
PCE prior to the
last exam (223)
PCE but not prior to
the last exam (425)
Never used
PCE (2,351)
Kruskal-Wallis
test: H =
PCE in academia is similar to doping in sports 3.7 (1.3) 3.2 (1.5)* 3.3 (1.4)* 3.8 (1.3) 59, P<0.001
In sports there are winners and loosers, PCE does
not necessarily result in loosers
2.8 (1.3) 3.1 (1.5)* 3.0 (1.3)* 2.7(1.2) 36, P<0.001
PCE is acceptable in a non-competitive
environment with no relative ratings
3.0 (1.4) 3.6 (1.3)* 3.3 (1.4)* 3.0 (1.3) 47, P<0.001
PCE is acceptable in a competitive environment
with relative ratings
1.7 (1.1) 2.4 (1.4)* 2.0 (1.2)* 1.6 (0.9) 91, P<0.001
Autonomy vs. Regulation N = 2,524 n = 189 n = 352 n = 1,983
Everyone is free to decide whether to use drugs for
PCE or not
3.5 (1.4) 3.9 (1.2)* 3.8 (1.3)* 3.5 (1.4) 31, P<0.001
I do not care if others use drugs for PCE while
studying
3.0 (1.3) 3.6 (1.4)* 3.3 (1.4)* 2.9 (1.3) 66, P<0.001
The university should should regulate drug use for
PCE
2.9 (1.4) 2.5 (1.4)* 2.6 (1.3)* 3.0 (1.3) 49, P<0.001
Not regulating PCE might result in unequal
educational and professional perspectives
3.5 (1.2) 3.1 (1.4)* 3.2 (1.3)* 3.6 (1.2) 36, P<0.001
Non-regulated access to NE substances increases
the pressure to use substances
3.2 (1.4) 3.0 (1.5) 3.2 (1.4) 3.2 (1.4) NS
Access to drugs is regulated sufﬁciently, speciﬁc
PCE regulations are unnecessary
2.5 (1.2) 2.9 (1.4)* 2.7 (1.2)* 2.4 (1.1) 32, P<0.001
Duties of academic institutions N = 2,502 n = 188 n = 345 n = 1,969
PCE use at universities may increase performance
requirements
3.4 (1.2) 3.5 (1.4) 3.3 (1.3) 3.4 (1.2) NS
We should invest more in research to develop
effective substances for PCE
2.2 (1.2) 2.8 (1.5)* 2.5 (1.3)* 2.1 (1.2) 74, P<0.001
The university should collect data on prevalence
and acceptance of PCE
3.8 (1.1) 3.8 (1.2) 3.8 (1.1) 3.8 (1.1) NS
The university should inform students about PCE
and associated risks
4.1 (1.0) 4.2 (1.1) 4.1 (1.0) 4.1 (1.0) NS
I would use safe drugs for PCE even if I gained an
advantage over others
2.1 (1.3) 3.2 (1.5)* 2.6 (1.4)* 1.8 (1.1) 252, P<0.001
PCE is a media-hype with no relevance to society 2.2 (1.1) 2.2 (1.1) 2.2 (1.1) 2.2 (1.0) NS
Values are mean (SD) of Likert scale rankings from 1 = strongly disagree, 2 = rather disagree, 3 = unsure, 4 = rather agree, 5 = strongly agree; bold
numbers indicate ratings > 3 = agree, or < 3 = disagree, p<0.001 (t-test for single means);
*signiﬁcant difference (p<0.001) compared to nonusers
doi:10.1371/journal.pone.0144402.t001
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environment but clearly more acceptable in a non-competitive environment (Z = 34.1,
p< 0.001). However, students who were experienced with PCE considered drug use for PCE as
more acceptable than nonusers in both environments (Table 1).
The participants agreed that everyone should be free to decide whether to use drugs for PCE
or not. Nonusers indicated that they would care if other students used drugs for PCE while
studying, whereas students who were experienced with PCE cared less about others’ PCE
(Table 1). Only nonusers supported the statement that unregulated access to pharmacological
cognitive enhancers might result in increased pressure to use drugs for PCE. The participants
disagreed with the view that access to substances for PCE is sufficiently controlled by existing
regulations for medications and substance use and that no specific regulations would be needed
for PCE. Nonusers were concerned that a lack of regulation might result in inequality in terms
of educational and professional development. However, they were unsure about whether the
university should regulate drug use for PCE (Table 1).
The participants tended to believe that PCE at universities may increase performance
requirements. Both users and nonusers of pharmacological cognitive enhancers similarly
agreed that the university should collect data on the prevalence and acceptance of drug use for
PCE among students. Furthermore, all of the students agreed that the university should inform
students neutrally about PCE and potential risks associated with such behavior. Finally, the
majority of nonusers (77%) indicated that they were not interested in PCE, even if safe sub-
stances were available (S3 Table).
Discussion
The present study had two main findings. First, Swiss university students presented rather neg-
ative attitudes toward PCE, considering the use of pharmacological cognitive enhancers fair
only when prescribed by a physician for the treatment of a mental disorder. Second, students
who used drugs for PCE reported higher acceptability of drug use for PCE compared with non-
users, independent of the context of use.
The present large and quantitative study showed that students raised concerns about PCE,
such as medical safety, fairness, and coercion, as previously established in the literature [5].
Very few students agreed with the non-prescribed use of methylphenidate or modafinil for
PCE (7%). The students agreed with PCE by fellow students only when they had a mental dis-
order that was diagnosed by a physician (64%) but not when they had an assumed disorder
(i.e., attention deficit disorder) without a formal diagnosis by a physician (26%). Students who
were experienced with PCE were more likely to agree with every form of substance use for PCE
compared with nonusers, confirming our primary hypothesis and the findings of previous
studies [5,7].
Medical safety and effects on personality
Many studies have weighed the benefits of PCE against its potential harms and found that non-
users were more concerned, and PCE users overestimated the beneficial cognitive-enhancing
effects [5]. Our findings revealed that medical safety was not the main concern about why PCE
is considered unacceptable. Nonusers agreed that PCE was problematic even if the substances
were safe, even if the use was controlled and occurred only occasionally (i.e., low risk of depen-
dence), and even if there were no negative consequences that could affect others (e.g., impaired
driving). Most nonusers indicated that they were unwilling to use hypothetically safe drugs for
PCE if they consequently gained an advantage over others (77%). Thus, considerations of fair-
ness (also see below) rather than a fear of adverse effects appears to be the reason for not using
PCE. A previous study among German students found that the willingness to use drugs for
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PCE decreased as the likelihood of expected side effects increased [3]. Similarly, a previous
Swiss study found that 85% of students worried about potential side effects of drugs that are
currently reported as being used for PCE [7]. Only one German study has presented contrast-
ing findings to date, showing that the majority of surveyed students would consider using
drugs for PCE if such drugs were safe [19]. Nevertheless, the present data indicate that other
considerations (see below) may be as important as safety of use [3]. Thus, considering the
views of the students, any regulations of drug use for PCE cannot be solely legitimized by
potential health risks.
A significant proportion of the students in the present study agreed with the opinion that
drug use for PCE alters users’ feelings and social behavior (61%) and even personality (46%).
Consistent with this finding, half of the students in a previous Swiss study who were inexperi-
enced with PCE and one-third of the students who were experienced with PCE indicated that
they had concerns about users “not being themselves anymore” [7]. Because the use of pharma-
cological cognitive enhancers while studying mainly occurs during exam periods and in low
quantities [6,15], substantial personality changes seem very unlikely. However, the perception
and subjective belief that changes in personality can occur are real concerns [7] that might be
explained by a lack of information on the main drugs that are discussed as cognitive enhancers.
Coercion
A concern of PCE is that other people may be pressured or coerced into using drugs for PCE
when taking notice of colleagues’ use. However, less than 3% of the students in our previous
study considered PCE as justifiable based solely on others’ use [6]. Nonetheless, peer pressure
and high demands on cognitive functioning in a competitive environment were previously
associated with increased approval of PCE [20,21]. More than half of the students who partici-
pated in the present study (56%) agreed that PCE may increase performance requirements at
universities. However, opinions about whether academic institutions have a duty to regulate
drug use for PCE were divided (equal proportions agreed and disagreed). Combined with the
findings that students were unsure about the effects of PCE on the quality of work and that a
large majority of students agreed that academic institutions should inform them about PCE
and associated risks, we suggest that coercion is a concern that results from a poor understand-
ing of the effects and risks of the drugs that are currently used for PCE. This is an important
finding of the present study, calling for providing students with more evidence-based informa-
tion on PCE.
Fairness
Overall, the use of hypothetically effective drugs for PCE by fellow students was considered
unfair by 70% of all respondents. A previous study found that 53% of German students consid-
ered PCE by fellow students unfair [14]. As expected, students who used drugs while studying
prior to the last exam (35%) and other PCE-experienced students (24%) were more likely to
consider that PCE was fair compared with nonusers (11%). This finding is consistent with pre-
vious research [5,7].
Furthermore, academic doping has often been compared with sports in terms of concerns
about fairness in the ethical debate about performance enhancement [10,12]. In the present
study, more than half of the students (58%) agreed that PCE in academia was similar to doping
in sports. In contrast, in a recent study, doping in sports was considered less ethical than aca-
demic doping [12]. The authors argued that this result indicates that individuals might have
been aware of the fact that intelligence associated with academic success was less malleable
than physical condition.
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Moreover, fellow students’ use of hypothetically effective drugs for PCE was considered fair
only when fellow students were diagnosed with a mental disorder by a physician. Using drugs
for PCE while having an assumed disorder (i.e. self-diagnosed attention deficit problems) but
without a physician’s diagnosis was considered much less fair. Similar to a previous study
among German students [14], only a minority of students in the present study approved PCE
among professors and surgeons (i.e., two professions with a high level of responsibility). Thus,
students in Switzerland do not think that people with jobs that are associated with a high level
of responsibility should cognitively enhance themselves [22].
Most of the participants in the present study (68%) agreed with the statement that results
that are obtained with PCE are less worthy of recognition. This finding was consistent with
other studies, indicating that achievements with PCE were considered less commendable than
performance that is achieved without such PCE [5,14]. A study among Swiss students showed
that nonusers were more concerned about not being proud of their achievements when having
used drugs for PCE compared with experienced users (42% vs. 19%) [7]. These indirect costs of
PCE because of nonusers’ concerns about the authenticity of performance while under the
influence of pharmacological cognitive enhancers might decrease the well-being of users [23].
Limitations
Because the response rate for the present survey was 10%, the study sample may not have been
necessarily representative of all Swiss students. Although all students from UniBas and ETHZ
were invited, only 5,000 of a total of 26,000 students who are currently enrolled at UZH who
had previously agreed to be contacted for participation in various studies could be invited.
Because the primary aim of the present study was to compare attitudes toward PCE between
users and nonusers, the lack of representativeness of the study population for all students is not
considered to be critically important. The strengths of the present study include its large sam-
ple size and the inclusion of both nonusers and two different groups of students who were
experienced with PCE. The sample sizes in other studies that investigated attitudes toward
PCE were often small [5] and sometimes limited to nonusers [13,15].
Conclusions
Swiss students’ main concerns about PCE were coercion and fairness. As expected, these con-
cerns were more prevalent among nonusers compared with students who were experienced
with PCE. More balanced information on PCE should be provided to students, and the future
monitoring of PCE is recommended.
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